Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Resveratrol improves endothelial cell markers impaired by plasma incubation from women who subsequently develop preeclampsia

Full text
Author(s):
Caldeira-Dias, Mayara [1] ; Montenegro, Marcelo F. [2] ; Bettiol, Heloisa [3] ; Barbieri, Marco Antonio [3] ; Cardoso, Viviane C. [3] ; Cavalli, Ricardo C. [4] ; Sandrim, Valeria C. [1]
Total Authors: 7
Affiliation:
[1] Univ Estadual Paulista UNESP, Inst Biosci Botucatu, Dept Pharmacol, BR-18680000 Botucatu, SP - Brazil
[2] Karolinska Inst Biomed, Dept Physiol & Pharmacol FYFA, S-17177 Stockholm - Sweden
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Gynecol & Obstet, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: HYPERTENSION RESEARCH; v. 42, n. 8, p. 1166-1174, AUG 2019.
Web of Science Citations: 0
Abstract

In this study, we demonstrated that plasma collected from women who subsequently developed preeclampsia caused increased heme oxygenase-1 (HO-1) production and decreased levels of nitric oxide (NO) markers in endothelial cells (HUVECs). Conversely, no changes in HO-1 or NO markers were found when HUVECs were treated with plasma from women who remained healthy throughout pregnancy. These alterations in HO-1 and NO markers were prevented by cotreatment with the polyphenol resveratrol, which also improved GSH levels. In addition, we evaluated changes induced by plasma incubation in the expression of genes and their related pathways associated with antioxidant defenses, such as Nrf2, ARE activity, and GSR. Collectively, our findings suggest that even before the appearance of clinical symptoms of preeclampsia, plasma from affected women is able to induce modifications in endothelial cells with respect to HO-1 production and NO markers. We believe that this in vitro strategy may offer an attractive alternative to the exploitation of candidate markers or screening molecules, such as resveratrol, for the prevention and management of preeclampsia. (AU)

FAPESP's process: 08/53593-0 - Etiological factors of preterm birth and consequences of perinatal factors in child health: birth cohorts in two Brazilian cities (BRISA project)
Grantee:Marco Antonio Barbieri
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 15/20461-8 - Role of NRF2 and HO-1 in preeclampsia: polymorphisms, circulating factors and in vitro assays
Grantee:Valeria Cristina Sandrim
Support Opportunities: Regular Research Grants